Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Source link
Related Posts
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
© 2025 The Politics Designed by The Politics.